The reasons may be that, after entering the human body, bevacizumab can bind to VEGF and then play the role of inhibiting the proliferation of vascular endothelial cells and neoangiogenesis, thereby achieving the purpose of targeted therapy, also, it has the efficacy of normalizing blood vessels, elevating the delivery of chemotherapy drugs within the tumor tissue, thus better exerting the antitumor effect. Here, VEGFA is linked to neoplasm.